Related references
Note: Only part of the references are listed.Anti-phospholipase A2 receptor antibody screening in nephrotic syndrome may identify a distinct subset of patients with primary membranous nephropathy
Roxana Jurubita et al.
INTERNATIONAL UROLOGY AND NEPHROLOGY (2022)
Membranous Nephropathy: Core Curriculum 2021
Loulwa Alsharhan et al.
AMERICAN JOURNAL OF KIDNEY DISEASES (2021)
Rituximab in Membranous Nephropathy
Philipp Gauckler et al.
KIDNEY INTERNATIONAL REPORTS (2021)
Efficacy and cost of different treatment in patients with idiopathic membranous nephropathy: A network meta-analysis and cost-effectiveness analysis
Pinyuan Dai et al.
INTERNATIONAL IMMUNOPHARMACOLOGY (2021)
The STARMEN trial indicates that alternating treatment with corticosteroids and cyclophosphamide is superior to sequential treatment with tacrolimus and rituximab in primary membranous nephropathy
Gema Fernandez-Juarez et al.
KIDNEY INTERNATIONAL (2021)
Autoantibodies in the Diagnosis, Monitoring, and Treatment of Membranous Nephropathy
Vladimir Tesar et al.
FRONTIERS IN IMMUNOLOGY (2021)
Rituximab Is Preferable to Cyclophosphamide for Treatment of Membranous Nephropathy: CON
Anne-Els van de Logt et al.
KIDNEY360 (2021)
Quantifying Duration of Proteinuria Remission and Association with Clinical Outcome in IgA Nephropathy
Mark Canney et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2021)
Management and treatment of glomerular diseases (part 1): conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference
Juergen Floege et al.
KIDNEY INTERNATIONAL (2019)
Rituximab or Cyclosporine in the Treatment of Membranous Nephropathy
F. C. Fervenza et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
The anti-PLA2R antibody in membranous nephropathy: what we know and what remains a decade after its discovery
Anne-Els Van de Logt et al.
KIDNEY INTERNATIONAL (2019)
Circulating anti-phospholipase A2 receptor antibodies as a diagnostic and prognostic marker in Greek patients with idiopathic membranous nephropathy - a retrospective cohort study
Simella Provatopoulou et al.
ROMANIAN JOURNAL OF INTERNAL MEDICINE (2019)
Treatment of primary membranous nephropathy: where are we now?
Andrea Angioi et al.
JOURNAL OF NEPHROLOGY (2018)
Epidemiology of IgA Nephropathy: A Global Perspective
Francesco Paolo Schena et al.
SEMINARS IN NEPHROLOGY (2018)
Safety of Rituximab Compared with Steroids and Cyclophosphamide for Idiopathic Membranous Nephropathy
Jan A. J. G. van den Brand et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2017)
Membranous nephropathy: New insights in therapeutic approach
Karine Dahan
NEPHROLOGIE & THERAPEUTIQUE (2017)
Rituximab for Treatment of Membranoproliferative Glomerulonephritis and C3 Glomerulopathies
Michael Rudnicki
BIOMED RESEARCH INTERNATIONAL (2017)
Clinical usefulness of autoantibodies to M-type phospholipase A2 receptor (PLA2R) for monitoring disease activity in idiopathic membranous nephropathy (IMN)
Antonella Radice et al.
AUTOIMMUNITY REVIEWS (2016)
Rituximab as a Rescue Therapy in Patients with Glomerulonephritis
Muhammad Ziad Souqiyyeh et al.
SAUDI JOURNAL OF KIDNEY DISEASES AND TRANSPLANTATION (2015)
Rituximab in Primary Membranous Nephropathy: First-Line Therapy, Why Not?
Paolo Cravedi et al.
NEPHRON CLINICAL PRACTICE (2014)
Off-label prescribing
J. Paul Seale
MEDICAL JOURNAL OF AUSTRALIA (2014)
Available evidence and outcome of off-label use of rituximab in clinical practice
I. Danes et al.
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY (2013)
Antiphospholipase A2 Receptor Antibody Titer and Subclass in Idiopathic Membranous Nephropathy
Julia M. Hofstra et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2012)
A New Equation to Estimate Glomerular Filtration Rate
Andrew S. Levey et al.
ANNALS OF INTERNAL MEDICINE (2009)